Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens

Bromo- and extra-terminal domain inhibitors (BETi) have exhibited therapeutic activities in many cancers. However, the mechanisms controlling BETi response and resistance are not well understood. We conducted genome-wide loss-of-function CRISPR screens using BETi-treated KMT2A-rearranged (KMT2A-r) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wright, Shaela, Hu, Jianzhong, Wang, Hong, Hyle, Judith, Zhang, Yang, Du, Guoqing, Konopleva, Marina Y., Kornblau, Steven M., Djekidel, Mohamed Nadhir, Rosikiewicz, Wojciech, Xu, Beisi, Lu, Rui, Yang, Jun J., Li, Chunliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2023
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120025/
https://www.ncbi.nlm.nih.gov/pubmed/37036970
http://dx.doi.org/10.1073/pnas.2220134120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120025/
https://www.ncbi.nlm.nih.gov/pubmed/37036970
http://dx.doi.org/10.1073/pnas.2220134120

Ejemplares similares